Transplantation: Cytomegalovirus prophylaxis: How long is enough?

Nature Reviews Nephrology

Volumn 6, Issue 1, 2010, Pages 13-14

  Kumar, Deepali ^a   Humar, Atul ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; FOSCARNET; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALGANCICLOVIR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; NEPHROTOXICITY; ORGAN DONOR; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT DURATION; VIREMIA; CHRONIC KIDNEY FAILURE; DISEASE TRANSMISSION; NOTE; POSTOPERATIVE COMPLICATION; RISK FACTOR; TIME; VIROLOGY;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TIME FACTORS;

EID: 74849132175     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.207     Document Type: Short Survey

References (7)

1. Luan, F. L. et al. six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J. Am. Soc. Nephrol. 20, 2449-2458 (2009).
2. Paya, C. et al. efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4, 611-620 (2004).
3. Humar, A. et al. The iMPACT study: valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMv disease [abstract]. Presented at the American Transplant Congress 2009.
4. Boivin, G. et al. Absence of cytomegalovirusresistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189, 1615-1618 (2004).
5. Humar, A. et al. Clinical utility of cytomegalovirus (CMv) serology testing in highrisk CMv D+/R- transplant recipients. Am. J. Transplant. 5, 1065-1070 (2005).
6. emery, v. C. et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032-2036 (2000).
7. Kumar, D. et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk organ transplant recipients. Am. J. Transplant. 9, 1214-1222 (2009).